{"id":"basal-insulin-and-exenatide","safety":{"commonSideEffects":[{"rate":"20–40","effect":"Nausea"},{"rate":"5–15","effect":"Vomiting"},{"rate":"variable, depends on insulin dose","effect":"Hypoglycemia"},{"rate":"10–20","effect":"Diarrhea"},{"rate":"5–10","effect":"Headache"},{"rate":"5–10","effect":"Injection site reactions"}]},"_chembl":{"chemblId":"CHEMBL1201631","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Basal insulin provides steady, long-acting glucose lowering throughout the day and night. Exenatide is a GLP-1 receptor agonist that enhances postprandial insulin secretion, slows gastric emptying, and promotes satiety, together improving glycemic control and often reducing body weight in type 2 diabetes patients.","oneSentence":"This combination uses basal insulin to provide background glucose control while exenatide stimulates insulin secretion and slows gastric emptying in response to meals.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:43:11.057Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus inadequately controlled on basal insulin monotherapy"}]},"trialDetails":[{"nctId":"NCT01107717","phase":"PHASE4","title":"Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2009-01","conditions":"Diabetes","enrollment":318},{"nctId":"NCT01524705","phase":"PHASE4","title":"FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)","status":"COMPLETED","sponsor":"University of Washington","startDate":"2012-08","conditions":"Type 2 Diabetes","enrollment":102},{"nctId":"NCT05161429","phase":"","title":"BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes","status":"UNKNOWN","sponsor":"Brigham and Women's Hospital","startDate":"2021-07-01","conditions":"Diabetes Mellitus, Type 2","enrollment":550000},{"nctId":"NCT02194595","phase":"PHASE3","title":"Preserving Beta-cell Function in Type 2 Diabetes With Exenatide and Insulin (PREVAIL)","status":"COMPLETED","sponsor":"Mount Sinai Hospital, Canada","startDate":"2014-09","conditions":"Type 2 Diabetes","enrollment":105},{"nctId":"NCT02072096","phase":"PHASE4","title":"A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2014-02","conditions":"Diabetes Mellitus, Type 2","enrollment":192},{"nctId":"NCT02455076","phase":"PHASE4","title":"Exenatide Inpatient Trial: A Randomized Controlled Pilot Trial on the Safety and Efficacy of Exenatide (Byetta®) Therapy for the Inpatient Management of Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Emory University","startDate":"2015-09","conditions":"Type 2 Diabetes","enrollment":150},{"nctId":"NCT03959865","phase":"","title":"GLP-1 REceptor Agonists and Real World EvIdeNce","status":"UNKNOWN","sponsor":"University of Padova","startDate":"2018-12-19","conditions":"Type 2 Diabetes","enrollment":6000},{"nctId":"NCT02229383","phase":"PHASE3","title":"Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-09-06","conditions":"Diabetes Mellitus","enrollment":464},{"nctId":"NCT02467920","phase":"PHASE4","title":"Efficacy and Safety of Basal Insulin Glargine Combination With Exenatide Bid vs Aspart30 in T2DM","status":"COMPLETED","sponsor":"Huazhong University of Science and Technology","startDate":"2015-08","conditions":"Type 2 Diabetes Mellitus","enrollment":349},{"nctId":"NCT02987348","phase":"","title":"Clinical Outcomes of Exenatide Versus Basal Insulin","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-06-30","conditions":"Type 2 Diabetes","enrollment":18000},{"nctId":"NCT02974244","phase":"","title":"Comparison of the Effectiveness and Tolerability of Exenatide Once-weekly Compared to Basal Insulins","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-10-28","conditions":"Type 2 Diabetes","enrollment":7000},{"nctId":"NCT02811484","phase":"PHASE4","title":"Efficacy of Exenatide-LAR and Dapagliflozin in Overweight/Obese, Insulin Treated Patients With Type 2 Diabetes","status":"WITHDRAWN","sponsor":"Weill Medical College of Cornell University","startDate":"2016-06","conditions":"Diabetes Mellitus, Type 2","enrollment":""},{"nctId":"NCT02895672","phase":"","title":"GLP-1/Basal Insulin Combination Therapy","status":"COMPLETED","sponsor":"Albany College of Pharmacy and Health Sciences","startDate":"2016-08","conditions":"Type 2 Diabetes Mellitus","enrollment":150},{"nctId":"NCT02887625","phase":"NA","title":"Exenatide Plus Pioglitazone Versus Insulin in Poorly Controlled T2DM","status":"UNKNOWN","sponsor":"Dr. Muhammad Abdulghani","startDate":"2015-02","conditions":"Type 2 Diabetes","enrollment":410},{"nctId":"NCT01060059","phase":"","title":"Exenatide and Basal Insulins Use in the Real Setting: an Observational Study in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-04","conditions":"Type 2 Diabetes Mellitus","enrollment":888},{"nctId":"NCT00960661","phase":"PHASE3","title":"A Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-09","conditions":"Type 2 Diabetes Mellitus","enrollment":1036},{"nctId":"NCT00360334","phase":"PHASE3","title":"A Study Comparing Exenatide With Basal Insulin in Achieving a Target HbA1c With Minimum Weight Gain in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-06","conditions":"Type 2 Diabetes","enrollment":235},{"nctId":"NCT00560417","phase":"PHASE3","title":"Comparison of Two Basal Insulins for Patients With Type 2 Diabetes Taking Oral Diabetes Medicines and Exenatide","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2007-11","conditions":"Diabetes Mellitus, Type 2","enrollment":339}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":126,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Basal insulin glargine","Exenatide"],"phase":"phase_3","status":"active","brandName":"Basal insulin and exenatide","genericName":"Basal insulin and exenatide","companyName":"Mount Sinai Hospital, Canada","companyId":"mount-sinai-hospital-canada","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses basal insulin to provide background glucose control while exenatide stimulates insulin secretion and slows gastric emptying in response to meals. Used for Type 2 diabetes mellitus inadequately controlled on basal insulin monotherapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}